When Wall Street turns bearish on a stock, it’s worth paying attention.
These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lose out in other business lines such as M&A advisory.
The past six months have been a windfall for Hims & Hers Health’s shareholders. The company’s stock price has jumped 90%, hitting $57.16 per share. This was partly due to its solid quarterly results, and the performance may have investors wondering how to approach the situation.
HIMS & HERS HEALTH INC (NYSE:HIMS) is a high-growth telehealth stock meeting Minervini’s Trend Template with strong earnings, revenue growth, and bullish technicals.
Companies that consistently increase their sales, margins, or returns on capital are usually rewarded with the best returns,
and those that can do all three for years on end are almost always the legendary stocks that return 100 times your money.
Curious about the most active stocks in today's session? Get a glimpse into the stocks that are generating the highest trading volume and capturing market attention.
Each trading day features hundreds of headlines and press releases on Benzinga Pro, a source for traders to see the latest news on the overall market and individual tickers.
The Zava acquisition will enable Hims & Hers to expand its footprint in the U.K. and launch operations in countries such as Germany, France, and Ireland, with other markets expected to follow soon.
Hims & Hers Health Inc (NYSE:HIMS) shares are trading higher Tuesday after the company announced an acceleration of its global expansion through the acquisition of ZAVA.
Personal health and wellness is one of the many secular tailwinds for healthcare companies. But speed bumps such as inventory destockings have persisted in the wake of COVID-19,
and over the past six months, the industry has pulled back by 12.9%. This drop was much worse than the S&P 500’s 1.9% loss.
